Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.35 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | KHK | P50053 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20329648 | 0.81 | TRPV4 (0.33) | TRPV4 | |
| SCHEMBL11982890 | 0.78 | CES2 (0.42) | CES2CES1 | |
| SCHEMBL13890151 | 0.76 | GRM4 (0.40) | TRPV4 | |
| SCHEMBL8739027 | 0.76 | TRPV4 (0.52) | TRPV4 | |
| SCHEMBL1996117 | 0.72 | TRPV4 (0.41) | TRPV4CES2CES1KHK | |
| SCHEMBL9491002 | 0.70 | TRPV4 (0.40) | TRPV4CES2CES1KHK | |
| SCHEMBL809090 | 0.69 | TRPV4 (0.48) | TRPV4CES2CES1KHK | |
| SCHEMBL31588414 | 0.69 | TRPV4 (0.48) | TRPV4CES2CES1KHK | |
| SCHEMBL23850353 | 0.68 | AR (0.46) | TRPV4CES2CES1 | |
| SCHEMBL20267322 | 0.68 | KHK (0.41) | TRPV4KHK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029190-A1 | COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF | GRM5, GRM2, GRM1 | TRPV4 980/4885CES2 1244/4885CES1 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.